Theravance Biopharma, Inc.
No SEC Form 4 filings for $TBPH in the last 30 days.
See all $TBPH insider activity →Theravance Biopharma reported Q2 2026 revenue of $20.7M, all from its Viatris collaboration, up 11% YoY. GAAP net loss was $5.9M. Cash and marketable securities were $387.7M at June 30, 2026. The company said a Zymeworks acquisition is expected to close in H2 2026, and it cited restructuring cost savings.
Theravance Biopharma, Inc. (TBPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622638d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update · Previously announced acquisition by Zymeworks expected to close in second half of 2026 · YUPELRI ® Collaboration Rev
Zymeworks Inc. agreed to acquire Theravance Biopharma, adding YUPELRI (revefenacin) for COPD. The deal values Theravance at $17/share, with a $350 million non-recourse note and $219 million cash plus Theravance’s estimated $360 million net cash at closing. YUPELRI U.S. net sales were $266.6M in 2025. Expected close in H2 2026.
Over the past 7 days, alphai's AI scored 2 news stories mentioning TBPH (Theravance Biopharma, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent TBPH coverage spans mergers & acquisitions, corporate actions and insider activity.
The quarter’s revenue mix, loss level, and cash position update near-term fundamentals, while the pending Zymeworks acquisition adds a deal-driven overhang.
Deal terms and timing shift the stock’s risk profile toward shareholder-approval and closing-condition outcomes, while operating updates support near-term fundamentals.
Zymeworks Inc. agreed to acquire Theravance Biopharma, adding YUPELRI (revefenacin) for COPD. The deal values Theravance at $17/share, with a $350 million non-recourse note and $219 million cash plus Theravance’s estimated $360 million net cash at closing. YUPELRI U.S. net sales were $266.6M in 2025. Expected close in H2 2026.
This is a routine insider sale with no stated 10b5-1 plan, but it does not disclose new fundamentals for TBPH.
Insider selling by a large owner can modestly affect near-term sentiment, but it is not a fundamental operating update.
alphai scores every news story that mentions TBPH with an AI model for sentiment and relevance, and aggregates insider trades from Theravance Biopharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Theravance Biopharma reported Q2 2026 revenue of $20.7M, all from its Viatris collaboration, up 11% YoY. GAAP net loss was $5.9M. Cash and marketable securities were $387.7M at June 30, 2026. The company said a Zymeworks acquisition is expected to close in H2 2026, and it cited restructuring cost savings.
2 min readTheravance Biopharma, Inc. (TBPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622638d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update · Previously announced acquisition by Zymeworks expected to close in second half of 2026 · YUPELRI ® Collaboration Rev
6 min readZymeworks Inc. agreed to acquire Theravance Biopharma, adding YUPELRI (revefenacin) for COPD. The deal values Theravance at $17/share, with a $350 million non-recourse note and $219 million cash plus Theravance’s estimated $360 million net cash at closing. YUPELRI U.S. net sales were $266.6M in 2025. Expected close in H2 2026.
5 min readSamaha Eli sold 6,964 indirectly-held shares of Theravance Biopharma, Inc. (TBPH) at an average of $17.14 ($17.04–$17.17, $0.12M total) across 2 trades over 2026-07-06 to 2026-07-07.
1 min readSamaha Eli sold 336,697 indirectly-held shares of Theravance Biopharma, Inc. (TBPH) at an average of $17.20 ($17.00–$17.23, $5.79M total) across 3 trades over 2026-06-29 to 2026-07-01.
2 min readZymeworks Inc. (Nasdaq:ZYME) said it will pay $929M in cash to acquire Theravance Biopharma Inc. (Nasdaq:TBPH). The offer is $17 per Theravance share, 3.6% below the prior close. Theravance’s ampreloxetine failed a March trial; its only marketed drug is Yupelri. Deal includes a one-year ampreloxetine monetization split and about $2.5B in Irish tax attributes.
4 min readZymeworks said it will acquire Theravance Biopharma in a $929 million cash deal, according to the company. The transaction is expected to affect Zymeworks’ shareholders and is being watched by investors for its impact on future pipeline and financial outlook. TBPH shares were reported down in pre-market trading.
2 min readTheravance Biopharma, Inc. (TBPH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 tm2619064d1_ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER By and Among THERAVANCE BIOPHARMA, INC. ZYMEWORKS INC. and ZYMEWORKS MERGER SUB 1 Dated as of June 28, 2026 Table of Contents Page Article I The Merger Section 1.1 The Merger 2 Section 1.2 Closing
4 min readTheravance Biopharma, Inc. (TBPH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001583107 0001583107 2026-06-19 2026-06-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report
2 min readTheravance Biopharma, Inc. (TBPH) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001583107 0001583107 2026-06-12 2026-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report
2 min read
